The way all this works is that for each presentation created, there's also an accompanying short URL (e.g. sld.im/12345) provided.
The overall structure is shaped like the letter "L" and contains two separate subdomains: an ARLD (armadillo-repeat-like domain) and an SLD (Spt16M-like domain).
This interrupted RING-finger has been termed the SIMPLE-like domain (SLD) [1].
Other functions that have been ascribed to LITAF [2], [7], [8], [9] have been called into question with evidence from a number of groups suggesting that the LITAF used in these experiments contained a nucleotide insertion that altered the reading frame in the C-terminal half of the protein, thereby eliminating the SLD [1], [10], [11].
Some TB hospitals in China have also reported TB strains that are resistant to all SLD [9], [10].
A prospective cohort study in eight countries demonstrated that bacterial strains of 43.7% of patients with MDR-TB already showed resistance against at least one SLD, 20.0% against one injectable drug and 12.9% against fluoroquinolones [ 36].
The set-up is based on a fiber-optics Michelson interferometer configuration with a superluminescent diode (SLD) (λ0 = 840 nm, Δλ = 50 nm; Superlum, Ireland) as a light source and a spectrometer consisting of a volume diffraction grating, and a 12-bit line-scan CMOS camera with 4096 pixels (Basler sprint spL4096-140k; Basler AGermanyasy) as a detector.
The SEC system set-up (Agilent Technologies 1260 Infinity) from PSS (Mainz, Germany) consisted of an isocratic pump, auto sampler without temperature regulation, an online degasser, an inline 0.2 μm filter, a refractive index detector (G1362A 1260 RID Agilent Technologies), viscometer (ETA-2010 PSS, Mainz) and MALLS (SLD 7000 PSS, Mainz).
Quantum dot-based SLDs [7 10] have been applied to OCT of skin tissue [11] using a QD SLD with 85-nm spectral bandwidth centered at 1250 nm, which resulted in an ~7-μm axial resolution of the OCT system [12].
XDR-TB, in addition to being resistance to at least isoniazid and rifampicin, is also resistance to at least three of the six main classes of second-line drugs (SLDs) [7].
